AstraZeneca’s Tagrisso hits the mark in late-stage lung cancer maintenance study
AstraZeneca’s Tagrisso has improved survival outcomes in a Phase III maintenance test for certain lung cancer patients, paving the way for the drug to expand …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.